Bridgewater Associates LP Buys 179,744 Shares of DaVita Inc. (NYSE:DVA)

Bridgewater Associates LP raised its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 298.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 239,970 shares of the company's stock after purchasing an additional 179,744 shares during the period. Bridgewater Associates LP owned 0.29% of DaVita worth $35,888,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in DaVita in the fourth quarter valued at approximately $41,000. Canada Post Corp Registered Pension Plan acquired a new stake in shares of DaVita during the fourth quarter worth $55,000. Venturi Wealth Management LLC raised its stake in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after buying an additional 152 shares during the last quarter. Versant Capital Management Inc boosted its position in DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after acquiring an additional 169 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in DaVita by 39.7% during the 4th quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after acquiring an additional 131 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on DVA. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Thursday, April 10th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Barclays upped their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Finally, Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $166.33.

DaVita Stock Down 4.1 %

Shares of DVA stock traded down $5.80 during trading hours on Monday, reaching $134.24. The company had a trading volume of 180,357 shares, compared to its average volume of 832,174. The company has a market cap of $10.74 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 12 month low of $128.69 and a 12 month high of $179.60. The business has a fifty day simple moving average of $149.13 and a 200-day simple moving average of $155.97.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.